Accuray Incorporated (NASDAQ:ARAY – Get Free Report) CFO Ali Pervaiz sold 8,404 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $2.06, for a total transaction of $17,312.24. Following the transaction, the chief financial officer now directly owns 394,138 shares of the company’s stock, valued at $811,924.28. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Accuray Stock Performance
Accuray stock traded down $0.07 during trading on Friday, hitting $1.92. The stock had a trading volume of 623,696 shares, compared to its average volume of 670,268. The company has a quick ratio of 0.78, a current ratio of 1.58 and a debt-to-equity ratio of 4.05. The stock’s 50 day moving average is $1.90 and its two-hundred day moving average is $2.05. Accuray Incorporated has a 1 year low of $1.40 and a 1 year high of $3.10. The stock has a market cap of $190.55 million, a price-to-earnings ratio of -8.91 and a beta of 1.45.
Accuray (NASDAQ:ARAY – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported $0.03 earnings per share for the quarter, hitting the consensus estimate of $0.03. Accuray had a negative return on equity of 33.39% and a negative net margin of 3.48%. The company had revenue of $134.29 million during the quarter, compared to the consensus estimate of $122.80 million. During the same quarter in the prior year, the company earned ($0.03) EPS. As a group, analysts predict that Accuray Incorporated will post -0.01 EPS for the current year.
Institutional Trading of Accuray
About Accuray
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
See Also
- Five stocks we like better than Accuray
- P/E Ratio Calculation: How to Assess Stocks
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- What is the Australian Securities Exchange (ASX)
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- The Most Important Warren Buffett Stock for Investors: His Own
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.